Monoclonal antibodies labeled with rhenium-186 using the MAG3 chelate: Relationship between the number of chelated groups and biodistribution characteristics

Journal of Nuclear Medicine

Volumn 37, Issue 2, 1996, Pages 352-362

  Van Gog, Frank B ^b   Visser, Gerard W M ^b   Klok, Rob ^b   Van Der Schors, Roel ^b   Snow, Gordon B ^b   Van Dongen, Guus A M S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

head and neck cancer; radioimmunoscintigraphy; radioimmunotherapy; rhenium 186 labeled monoclonal antibody; technetium labeled monoclonal antibody

Indexed keywords

IODINE 125; MONOCLONAL ANTIBODY; RHENIUM 186; TECHNETIUM 99M;

ANTIBODY AFFINITY; ARTICLE; CHELATION; HEAD AND NECK CANCER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; IMMUNOSCINTIGRAPHY; ISOELECTRIC FOCUSING; NUDE MOUSE; PRIORITY JOURNAL; QUALITY CONTROL; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION;

ANIMALS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; MICE; MICE, NUDE; RADIOIMMUNODETECTION; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RHENIUM; TECHNETIUM TC 99M MERTIATIDE; TISSUE DISTRIBUTION;

EID: 0029874881     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Hong WK, Lippman SM, Wolf GT. Recent advances in head and neck cancer - larynx preservation and cancer chemoprevention - the seventeenth annual Richard and Hinda Rosenthal foundation award lecture. Cancer Res 1993,53.5113-5120
2. Stell PM, Rawson NSB. Adjuvant chemotherapy in head and neck cancer Br J Cancer 1990;61.779-787.
3. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993;328:184-193.
4. Riethmüller G, Schneider-Gadicke E, Schlimok G et al. Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes C colorectal carcinoma Lancet 1994;343:1177-1183
5. Nossal GJV Minimal residual disease as the target for immunotherapy of cancer. Lancet 1994;343:1172-1174
6. Wessels BW, Harisiadis L, Carabell SC. Dosimetry and radiobiological efficacy of clinical radiotherapy [Abstract] J Nucl Med 1989;30:827.
7. Schrijvers AHGJ, Quak JJ, Uyterlinde AM, et al. MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck Cancer Res 1993,53:4383-4390.
8. 2. Cancer Res 1992,52 2569-2574.
9. De Bree R, Roos JC, Quak JJ, Den Hollander W, Snow GB, Van Dongen GAMS. Clinical screening of monoclonal antibodies 323 A3, cSF-25, and K928 for suitability of targeting tumors in the upper-aerodigestive and respiratory tract Nucl Med Commun 1994;15:613-627.
10. 2. J Nucl Med 1994,35:775-783.
11. Van Dongen GAMS, Brakenhoff RH, De Bree R, Gerretsen M, Quak JJ, Snow GB. Progress in radioimmunotherapy of head and neck cancer. Review. Oncol Reports 1994;1:259-264.
12. 2 in patients with head and neck cancer. Clin Cancer Res 1995;1:277-286
13. De Bree R, Roos JC, Quak JJ, Den Hollander W, Snow GB, Van Dongen GAMS. Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer. Clin Cancer Res 1995;1.591-598.
14. Coursey BM, Cessna, Garcia-Torano E. The standardization and decay scheme of rhenium-186 Int J Radiat Appl Instrum Part A 1991;42:865-869.
15. 99mTc. Int J Radiat Appl Instrum B 1989,16.171-176
16. Verbruggen AM. Radiopharmaceuticals: state of the art Eur J Nucl Med 1990,17: 346-364.
17. Hnatowich DJ Antibody radiolabeling, problems and promises Int J Radiat Appl Instrum B 1990, 17 49-55
18. Srivastava SC, Mease RC. Progress in research on ligands, nuclides and techniques for labeling monoclonal antibodies. Int J Radiat Appl Instrum Part B 1991,18:589-603
19. 99mTc. Int J Radiat Appl Instrum Part B 1991;18:667-676.
20. Griffiths GL, Goldenberg DM, Knapp FF, Callahan AP, Chang CH, Hansen HJ. Direct radiolabeling of monoclonal antibodies with generator- produced rhentum-188 for radioimmunotherapy - labeling and animal biodistribution studies Cancer Res 1991; 51 4594-4602.
21. Griffiths GL, Goldenberg DM, Diril H, Hansen HJ. Technetium-99m, rhenium-186 and rhenium-188 direct-labeled antibodies Cancer 1994;73:761-768
22. John E, Thakur ML, DeFulvio J, McDevitt MR, Damjanov I Rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: preparation and evaluation. J Nucl Med 1993;34:260-267.
23. Breitz HB, Weiden PL, Vanderheyden JL et al Clinical experience with rhenium-186 labeled monoclonal antibodies for radioimmunotherapy results of phase-1 trials J Nucl Med 1992;33:1099-1112
24. 4 chelate in vitro and in vivo using tumor-bearing nude mice. Nucl Med Biol 1992,19:205-212.
25. 186Re labeling of monoclonal antibodies. Cancer 1994;73:769-773.
26. Goldrosen MH, Biddle WC, Pancook J, et al Biodistribution, pharmacokinetic and imaging studies with Re-186-labeled NR-LU-10 whole antibody in LS174T colonic tumor-bearing mice. Cancer Res 1990;50:7973-7978.
27. Beaumier PL, Venkatesan P, Vanderheyden J-L, et al. Rhenium-186 radioimmunotherapy of small-cell lung carcinoma xenografts in nude mice. Cancer Res 1991;51: 676-681.
28. Breitz HB, Fisher DR, Weiden PL, et al Dosimetry of rhenium-186-labeled monoclonal antibodies - methods, prediction from technetium-99m-labeled antibodies and results of phase 1 trials J Nucl Med 1993,34:908-917.
29. Jacobs AJ, Fer M, Su FM, et al. A phase 1 trial of rhenium-186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma toxicity and clinical response. Obstet Gynecol 1993;82:586-593.
30. 186Re using the MAG3 chelate for radioimmunotherapy of cancer a technical protocol. J Nucl Med 1993;34.1953-1963
31. Quak JJ, Schrijvers AHGJ, Brakkee JGP, et al. Expression and characterization of two differentiation antigens in stratified squamous epithelia and carcinomas. Int J Cancer 1992;50:507-513.
32. Takahashi H, Wilson B, Ozturk M, et al. In vivo localization of human colon adenocarcinoma by monoclonal antibody binding to a highly expressed cell surface antigen Cancer Res 1988;48.6573-6579.
33. Takahashi H, Nakada T, Puisieux I Inhibition of human colon cancer growth by antibody-directed human LAK. cells in SCID mice. Science 1993,259.1460-1463
34. Brakenhoff RH, Van Gog FB, Looney JE, Van Walsum M, Snow GB, Van Dongen GAMS Construction and characterization of the chimeric monoclonal antibody E48 for therapy of head and neck cancer Cancer Immunol Immunother 1995,40 191-200.
35. Li KW, Holling T, de With ND, Geraerts WPM Purification and characterization of a novel tetradecapeptide that modulates oesophagus motility in Lymnaea stagnalis, Biochem Biophys Res Commun 1993,197:1056-1061
36. 131I-labeled monoclonal antibody E48. Br J Cancer 1992;66.496-502
37. Boniface GR, Izard ME, Walker KZ, et al. Labeling of monoclonal antibodies with Samarium-153 for combined radioimmunoscintigraphy and radioimmunotherapy. J Nucl Med 1989;30:683-691.
38. 133I-labeled forms of monoclonal antibodies SEN7 and SWA20 directed against small-cell lung cancer Int J Cancer 1994,8:43-48
39. Pèlegrin A, Folli S, Buchegger F, Mach J-P, Wagnières G, Van den Bergh H. Antibody-fluorescein conjugates for photoimmunodiagnosis of human colon carcinoma in nude mice Cancer 1991,67 2529-2537.
40. Kasma S, Rao TN, Srinivasan A, et al. Development and biological evaluation of a kit for preformed chelate technetium-99m radiolabeling of an antibody Fab fragment using a diamide dimercaptide chelating agent J Nucl Med 1991,32:1445-1451.
41. Goldenberg DM, Griffiths GL. Radioimmunotherapy of cancer arming the missiles [Editorial] J Nucl Med 1992,33 1110-1112
42. John E, Thakur ML, Wilder S, Alauddin MM, Epstein AL. Technetium-99m-labeled monoclonal antibodies: influence of technetium-99m binding sites J Nucl Med 1994;35:876-881.
43. 186Re-labeled monoclonal antibody E48. Cell Biophys 1994;24:135-142
44. 186Re-labeled monoclonal antibody E48 immunoglobulin G-mediated therapy of human head and neck squamous-cell carcinoma xenografts. Cancer Res 1993;53 3524-3529.